{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T10:16:27Z","timestamp":1785838587800,"version":"3.56.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1136\/ijgc-2020-002032","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T17:05:30Z","timestamp":1604077530000},"page":"352-359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer"],"prefix":"10.1016","volume":"31","author":[{"given":"Annabelle","family":"Brennan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"Rees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Hickey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-002032_bb0010","first-page":"394","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1136\/ijgc-2020-002032_bb0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/S1470-2045(18)30836-2","article-title":"Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study","volume":"20","author":"Simms","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01440","article-title":"Global, regional, and national burden of endometrial cancer, 1990-2017: results from the global burden of disease study, 2017","volume":"9","author":"Zhang","year":"2019","journal-title":"Front Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.2140","article-title":"Exome sequencing-based screening for BRCA1\/2 expected pathogenic variants among adult Biobank participants","volume":"1","author":"Manickam","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1136\/ijgc-2020-002032_bb0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0235038","article-title":"Cost-Effectiveness analysis of genetic diagnostic strategies for Lynch syndrome in Italy","volume":"15","author":"Pastorino","year":"2020","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2020-002032_bb0035","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.2019.10987","article-title":"Risk assessment, genetic counseling, and genetic testing for BRCA-Related cancer: US preventive services Task force recommendation statement","volume":"322","author":"US Preventive Services Task Force","year":"2019","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2020-002032_bb0040","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/GME.0000000000001176","article-title":"Risk factors for sexual dysfunction in BRCA mutation carriers after risk-reducing salpingo-oophorectomy","volume":"26","author":"Chan","year":"2019","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10689-010-9384-z","article-title":"What I wish I'd known before surgery: BRCA carriers' perspectives after bilateral salipingo-oophorectomy","volume":"10","author":"Campfield Bonadies","year":"2011","journal-title":"Fam Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0050","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/GME.0b013e3182976f46","article-title":"Nature and severity of menopausal symptoms and their impact on quality of life and sexual function in cancer survivors compared with women without a cancer history","volume":"21","author":"Marino","year":"2014","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0055","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1080\/13697137.2019.1646718","article-title":"Managing menopausal symptoms after cancer","volume":"22","author":"Szabo","year":"2019","journal-title":"Climacteric"},{"key":"10.1136\/ijgc-2020-002032_bb0060","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3109\/13697137.2015.1020484","article-title":"Long-Term health consequences of premature or early menopause and considerations for management","volume":"18","author":"Faubion","year":"2015","journal-title":"Climacteric"},{"key":"10.1136\/ijgc-2020-002032_bb0065","article-title":"Oral oestrogen and combined oestrogen\/progestogen therapy versus placebo for hot flushes","volume":"18","author":"Maclennan","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2020-002032_bb0070","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/GME.0000000000000921","article-title":"The 2017 hormone therapy position statement of the North American menopause Society","volume":"24","author":"The NAMS 2017 Hormone Therapy Position Statement Advisory Panel","year":"2017","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0075","first-page":"1","author":"National Institute for Health and Care Excellence","year":"2015"},{"key":"10.1136\/ijgc-2020-002032_bb0080","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/humrep\/deaa124","article-title":"Type of menopause, age of menopause and variations in the risk of incident cardiovascular disease: pooled analysis of individual data from 10 international studies","volume":"35","author":"Zhu","year":"2020","journal-title":"Hum Reprod"},{"key":"10.1136\/ijgc-2020-002032_bb0085","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.psyneuen.2019.03.013","article-title":"Surgical menopause in association with cognitive function and risk of dementia: a systematic review and meta-analysis","volume":"106","author":"Georgakis","year":"2019","journal-title":"Psychoneuroendocrinology"},{"key":"10.1136\/ijgc-2020-002032_bb0090","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ajog.2019.08.043","article-title":"Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy","volume":"222","author":"Crean-Tate","year":"2020","journal-title":"Am J Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0095","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/GME.0000000000000956","article-title":"Breast cancer, endometrial cancer, and cardiovascular events in participants who used vaginal estrogen in the women's health Initiative observational study","volume":"25","author":"Crandall","year":"2018","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0100","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JOP.2011.000352","article-title":"Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator","volume":"8","author":"Wills","year":"2012","journal-title":"J Oncol Pract"},{"key":"10.1136\/ijgc-2020-002032_bb0105","unstructured":"Vagifem 10 micrograms vaginal tablets . Available: https:\/\/www.medicines.org.uk\/emc\/product\/5719\/smpc [Accessed 7 Jan 2020]."},{"key":"10.1136\/ijgc-2020-002032_bb0110","first-page":"643","article-title":"Evaluating the efficacy of vaginal dehydroepiandosterone for vaginal symptoms in postmenopausal cancer survivors: NCCTG N10C1 (Alliance)","volume":"26","author":"Barton","year":"2018","journal-title":"Support Care Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0115","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1210\/jc.2019-01603","article-title":"Global consensus position statement on the use of testosterone therapy for women","volume":"104","author":"Davis","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1136\/ijgc-2020-002032_bb0120","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1097\/GME.0000000000001363","article-title":"Cognitive behavior therapy for menopausal symptoms (CBT-Meno): a randomized controlled trial","volume":"26","author":"Green","year":"2019","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0125","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1001\/jamainternmed.2018.0116","article-title":"Efficacy of vaginal estradiol or vaginal Moisturizer vs placebo for treating postmenopausal vulvovaginal symptoms: a randomized clinical trial","volume":"178","author":"Mitchell","year":"2018","journal-title":"JAMA Intern Med"},{"key":"10.1136\/ijgc-2020-002032_bb0130","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1097\/GME.0000000000000672","article-title":"Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and\/or hormonal therapy for breast cancer: a retrospective study","volume":"23","author":"Pagano","year":"2016","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0135","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/GME.0000000000000761","article-title":"Vaginal erbium laser as second-generation thermotherapy for the genitourinary syndrome of menopause: a pilot study in breast cancer survivors","volume":"24","author":"Gambacciani","year":"2016","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0140","first-page":"417","article-title":"Adenocarcinoma of the endometrium in women 40 years of age or younger","volume":"64","author":"Gallup","year":"1984","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0145","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1136\/ijgc-2019-001105","article-title":"Endometrial cancer in young women: prognostic factors and treatment outcomes in women aged \u226440 years","volume":"30","author":"Son","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0150","doi-asserted-by":"crossref","first-page":"417","DOI":"10.5468\/ogs.19169","article-title":"Fertility-Sparing treatment in early endometrial cancer: current state and future strategies","volume":"63","author":"Obermair","year":"2020","journal-title":"Obstet Gynecol Sci"},{"key":"10.1136\/ijgc-2020-002032_bb0155","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/01.AOG.0000255980.88205.15","article-title":"Prognostic factors for uterine cancer in reproductive-aged women","volume":"109","author":"Lee","year":"2007","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0160","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/annonc\/mdv484","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis treatment and follow-up [published correction appears in Ann Oncol","volume":"27","author":"Colombo","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0165","doi-asserted-by":"crossref","first-page":"59940","DOI":"10.18632\/oncotarget.18404","article-title":"Ovarian preservation improves overall survival in young patients with early-stage endometrial cancer","volume":"8","author":"Jia","year":"2017","journal-title":"Oncotarget"},{"key":"10.1136\/ijgc-2020-002032_bb0170","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1097\/AOG.0000000000001647","article-title":"Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer","volume":"128","author":"Matsuo","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0175","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1200\/JCO.2005.02.8464","article-title":"Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a gynecologic Oncology Group study","volume":"24","author":"Barakat","year":"2006","journal-title":"JCO"},{"key":"10.1136\/ijgc-2020-002032_bb0180","article-title":"Hormone replacement therapy for women previously treated for endometrial cancer","volume":"5","author":"Edey","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2020-002032_bb0185","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ijgc-2020-001309","article-title":"Improving response to progestin treatment of low-grade endometrial cancer","volume":"30","author":"Baxter","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0190","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/cncr.28476","article-title":"Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and\/or progesterone receptors","volume":"120","author":"George","year":"2014","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0195","article-title":"Non-Hormonal treatments for menopausal symptoms","volume":"359","author":"Hickey","year":"2017","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2020-002032_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2019.00801","article-title":"Menopausal hormone replacement therapy and the risk of ovarian cancer: a meta-analysis","volume":"10","author":"Liu","year":"2019","journal-title":"Front Endocrinol"},{"key":"10.1136\/ijgc-2020-002032_bb0205","author":"American Cancer Society","year":"2019","journal-title":"Cancer facts"},{"key":"10.1136\/ijgc-2020-002032_bb0210","article-title":"Hormone therapy for ovarian cancer survivors: systematic review and meta-analysis","volume":"23","author":"Pergialiotis","year":"2016","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ygyno.2015.07.109","article-title":"Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis","volume":"139","author":"Li","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0220","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1200\/JCO.2015.60.9719","article-title":"Adjuvant hormone therapy may improve survival in epithelial ovarian cancer: results of the AHT randomized trial","volume":"33","author":"Eeles","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0225","doi-asserted-by":"crossref","first-page":"673","DOI":"10.3109\/13697137.2013.806472","article-title":"The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China","volume":"16","author":"Wen","year":"2013","journal-title":"Climacteric"},{"key":"10.1136\/ijgc-2020-002032_bb0230","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/(SICI)1097-0142(19990915)86:6<1013::AID-CNCR17>3.0.CO;2-1","article-title":"Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial","volume":"86","author":"Guidozzi","year":"1999","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0235","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1097\/pgp.0b013e31803025cd","article-title":"Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis","volume":"26","author":"Wong","year":"2007","journal-title":"Int J Gynecol Pathol"},{"key":"10.1136\/ijgc-2020-002032_bb0240","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.ygyno.2012.02.037","article-title":"Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum","volume":"125","author":"Gershenson","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0245","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2016.71.0632","article-title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","volume":"35","author":"Gershenson","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0250","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s10549-016-3765-4","article-title":"Informing hot flash treatment decisions for breast cancer survivors: a systematic review of randomized trials comparing active interventions","volume":"156","author":"Johns","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1136\/ijgc-2020-002032_bb0255","author":"Food and Drug Administration (FDA)","year":"2019","journal-title":"Drug safety communication"},{"key":"10.1136\/ijgc-2020-002032_bb0260","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/AOG.0000000000001396","article-title":"Hormone use after nonserous epithelial ovarian cancer: overall and disease-free survival","volume":"127","author":"Power","year":"2016","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0265","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-20-1268","article-title":"Endometrial cancer molecular risk stratification is equally prognostic for endometrioid ovarian carcinoma","author":"Kr\u00e4mer","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2020-002032_bb0270","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.maturitas.2020.01.005","article-title":"European menopause and Andropause Society (EMAS) and international gynecologic cancer Society (IGCS) position statement on managing the menopause after gynecological cancer: focus on menopausal symptoms and osteoporosis","volume":"134","author":"Rees","year":"2020","journal-title":"Maturitas"},{"key":"10.1136\/ijgc-2020-002032_bb0275","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1136\/jcp.2006.040030","article-title":"Ovarian clear cell adenocarcinoma: a continuing enigma","volume":"60","author":"Tan","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1136\/ijgc-2020-002032_bb0280","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1001\/jama.292.13.1573","article-title":"Estrogen plus progestin and risk of venous thrombosis","volume":"292","author":"Cushman","year":"2004","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2020-002032_bb0285","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/GME.0000000000000611","article-title":"Risk of venous thromboembolism associated with local and systemic use of hormone therapy in peri- and postmenopausal women and in relation to type and route of administration","volume":"23","author":"Bergendal","year":"2016","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0290","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/AOG.0000000000003579","article-title":"Effects of Gastrointestinal-Type chemotherapy in women with ovarian mucinous carcinoma","volume":"134","author":"Kurnit","year":"2019","journal-title":"Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0295","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics10010052","article-title":"Mucinous cancer of the ovary: overview and current status","volume":"10","author":"Babaier","year":"2020","journal-title":"Diagnostics"},{"key":"10.1136\/ijgc-2020-002032_bb0300","first-page":"163","article-title":"Incidence of chemotherapy-induced amenorrhea in premenopausal women treated with adjuvant FOLFOX for colorectal cancer","volume":"12","author":"Cercek","year":"2013","journal-title":"Clin Colorectal Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0305","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1056\/NEJMoa1909707","article-title":"Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer","volume":"381","author":"Coleman","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-002032_bb0310","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2020-002032_bb0315","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/GRF.0000000000000513","article-title":"Immunotherapy for gynecologic cancer: current applications and future directions","volume":"63","author":"Lynam","year":"2020","journal-title":"Clin Obstet Gynecol"},{"key":"10.1136\/ijgc-2020-002032_bb0320","doi-asserted-by":"crossref","first-page":"2792","DOI":"10.1200\/JCO.2006.08.4590","article-title":"Reproductive and sexual function after platinum-based chemotherapy in long-term ovarian germ cell tumor survivors: a gynecologic Oncology Group study","volume":"25","author":"Gershenson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0325","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"van Meurs","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0330","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1006\/gyno.2001.6183","article-title":"Granulosa cell tumor of the ovary: a population-based study of 37 women with stage I disease","volume":"81","author":"Lauszus","year":"2001","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0335","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/ijc.23724","article-title":"Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer","volume":"123","author":"Sk\u00edrnisd\u00f3ttir","year":"2008","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0340","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.bpobgyn.2016.09.012","article-title":"Management of borderline ovarian tumours","volume":"41","author":"Gershenson","year":"2017","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1136\/ijgc-2020-002032_bb0345","unstructured":"National Cancer Institute . Surveillance, epidemiology, and end results program. Available: https:\/\/seer.cancer.gov\/statfacts\/html\/cervix.html"},{"key":"10.1136\/ijgc-2020-002032_bb0350","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/IGC.0000000000001216","article-title":"The European Society of gynaecological Oncology\/European Society for radiotherapy and Oncology\/European Society of pathology guidelines for the management of patients with cervical cancer","volume":"28","author":"Cibula","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0355","article-title":"Hormone therapy after uterine cervical cancer treatment: a Swedish population-based study","volume":"22","author":"Everhov","year":"2015","journal-title":"Menopause"},{"key":"10.1136\/ijgc-2020-002032_bb0360","first-page":"1341","article-title":"Oestrogen and progesterone receptor expression in patients with adenocarcinoma of the uterine cervix and correlation with various clinicopathological parameters","volume":"30","author":"Bodner","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1136\/ijgc-2020-002032_bb0365","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0090-8258(87)90270-8","article-title":"Hormonal replacement therapy in patients after cervical cancer treatment","volume":"26","author":"Ploch","year":"1987","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0370","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/gyno.2000.5731","article-title":"Use of hormone replacement therapy and adenocarcinomas and squamous cell carcinomas of the uterine cervix","volume":"77","author":"Lacey","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0375","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1080\/13697137.2017.1285879","article-title":"Impact of risk-reducing salpingo-oophorectomy in premenopausal women","volume":"20","author":"Vermeulen","year":"2017","journal-title":"Climacteric"},{"key":"10.1136\/ijgc-2020-002032_bb0380","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2018.0211","article-title":"Hormone replacement therapy after oophorectomy and breast cancer risk among BRCA1 mutation carriers","volume":"4","author":"Kotsopoulos","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0385","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2018.12.014","article-title":"Hormone replacement therapy after risk reducing salpingo-oophorectomy in patients with BRCA1 or BRCA2 mutations; a systematic review of risks and benefits","volume":"153","author":"Gordhandas","year":"2019","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0390","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2010.12.326","article-title":"The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation","volume":"121","author":"Finch","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0395","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejca.2017.07.018","article-title":"Hormone replacement therapy after risk-reducing salpingo-oophorectomy minimises endocrine and sexual problems: a prospective study","volume":"84","author":"Vermeulen","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2020-002032_bb0400","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1200\/JCO.2018.78.4777","article-title":"Cancer risks for PMS2-Associated Lynch syndrome","volume":"36","author":"Ten Broeke","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2020-002032_bb0405","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1038\/s41436-019-0489-y","article-title":"The Manchester international consensus group recommendations for the management of gynecological cancers in Lynch syndrome","volume":"21","author":"Crosbie","year":"2019","journal-title":"Genet Med"},{"key":"10.1136\/ijgc-2020-002032_bb0410","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072290","article-title":"Risk-Reducing gynecological surgery in Lynch syndrome: results of an international survey from the prospective Lynch syndrome database","volume":"9","author":"Dominguez-Valentin","year":"2020","journal-title":"J Clin Med"},{"key":"10.1136\/ijgc-2020-002032_bb0415","first-page":"999","article-title":"Cancer risk in des daughters","volume":"21","author":"Verloop","year":"2010","journal-title":"Cancer Causes Control"},{"key":"10.1136\/ijgc-2020-002032_bb0420","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.maturitas.2012.03.002","article-title":"Diethylstilboestrol--a long-term legacy","volume":"72","author":"Harris","year":"2012","journal-title":"Maturitas"},{"key":"10.1136\/ijgc-2020-002032_bb0425","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1056\/NEJMoa1013961","article-title":"Adverse health outcomes in women exposed in utero to diethylstilbestrol","volume":"365","author":"Hoover","year":"2011","journal-title":"N Engl J Med"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2402022X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X2402022X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-002032","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:38:35Z","timestamp":1753223915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X2402022X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1048891X2402022X"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-002032","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of menopausal symptoms and ovarian function preservation in women with gynecological cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-002032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}